Earnings summaries and quarterly performance for DANAHER CORP /DE/.
Executive leadership at DANAHER CORP /DE/.
Rainer Blair
Detailed
Chief Executive Officer
CEO
BE
Brian Ellis
Detailed
Senior Vice President
GC
Georgeann Couchara
Detailed
Senior Vice President, Human Resources
JG
Jose-Carlos Gutierrez-Ramos
Detailed
Senior Vice President and Chief Science Officer
MG
Matthew Gugino
Detailed
Executive Vice President and Chief Financial Officer (effective February 28, 2026)
MM
Matthew McGrew
Detailed
Executive Vice President and Chief Financial Officer
MR
Mitchell Rales
Detailed
Chairman of the Executive Committee
SR
Steven Rales
Detailed
Chairman of the Board
Board of directors at DANAHER CORP /DE/.
AS
A. Shane Sanders
Detailed
Director
AS
Alan Spoon
Detailed
Director
CL
Charles Lamanna
Detailed
Director
EZ
Elias Zerhouni
Detailed
Director
FD
Feroz Dewan
Detailed
Director
JM
Jessica Mega
Detailed
Director
JS
John Schwieters
Detailed
Director
LF
Linda Filler
Detailed
Lead Independent Director
RS
Raymond Stevens
Detailed
Director
TL
Teri List
Detailed
Director
Research analysts who have asked questions during DANAHER CORP /DE/ earnings calls.
SD
Scott Davis
Melius Research
8 questions for DHR
Also covers: CARR, DD, DOV +16 more
Michael Ryskin
Bank of America Merrill Lynch
7 questions for DHR
Also covers: A, ALGN, AVTR +28 more
Tycho Peterson
Jefferies
7 questions for DHR
Also covers: A, AVTR, BIO +22 more
Jack Meehan
Nephron Research LLC
6 questions for DHR
Also covers: A, AVTR, BIO +17 more
Vijay Kumar
Evercore ISI
6 questions for DHR
Also covers: A, ABT, AVTR +21 more
Doug Schenkel
Wolfe Research LLC
5 questions for DHR
Also covers: A, AVTR, BRKR +15 more
DB
Dan Brennan
UBS
4 questions for DHR
Also covers: A, ADPT, MDXH +10 more
PS
Puneet Souda
Leerink Partners
4 questions for DHR
Also covers: A, ABCL, BRKR +20 more
Daniel Brennan
TD Cowen
3 questions for DHR
Also covers: A, ADPT, AVTR +24 more
DL
Dan Leonard
UBS Group AG
3 questions for DHR
Also covers: A, AVTR, BIO +9 more
Douglas Schenkel
Wolfe Research, LLC
3 questions for DHR
Also covers: A, AVTR, BRKR +21 more
Patrick Donnelly
Citi
2 questions for DHR
Also covers: A, AVTR, BIO +22 more
RV
Rachel Vatnsdal Olson
JPMorgan
2 questions for DHR
Also covers: A, ADPT, AKYA +14 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
1 question for DHR
Also covers: A, AVTR, CDXS +15 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for DHR
Also covers: A, AVTR, BIO +15 more
Luke Sergott
Barclays
1 question for DHR
Also covers: A, AVTR, BRKR +19 more
MW
Michael Wriston
Bank of America
1 question for DHR
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for DHR
Also covers: A, AKYA, AVTR +11 more
Recent press releases and 8-K filings for DHR.
Danaher forecasts bioprocess filtration market to grow 13.1% CAGR to $15.6 B by 2030
DHR
New Projects/Investments
- BCC Research projects the bioprocess filtration market to expand from $8.4 billion in 2025 to $15.6 billion by 2030, achieving a 13.1% CAGR over the period.
- Growth is driven by increasing demand for biologics, gene therapies, and cell-based treatments, expansion of CDMOs/CMOs, and rising adoption of single-use filtration systems under stringent GMP standards.
- The consumables segment (cartridges, capsules, membranes, single-use assemblies) is expected to remain dominant through 2030.
- North America leads the market, supported by major suppliers including Danaher’s Cytiva, Merck KGaA, Sartorius, and Repligen.
- Danaher’s Cytiva invested $1.6 billion in 2025 to expand global filtration and device capacity—boosting its Ilfracombe, U.K. site by 81%.
2 days ago
Danaher reports Q4 2025 results
DHR
Earnings
Guidance Update
- Danaher’s Q4 2025 sales were $6.8 billion, with 2.5% core revenue growth; adjusted EPS was $2.23, and free cash flow totaled $1.8 billion.
- Full-year 2025 sales reached $24.6 billion, core revenue grew 2%, adjusted EPS was $7.80 (+4.5%), and free cash flow was $5.3 billion (145% conversion).
- For 2026, Danaher guided to 3%–6% core revenue growth, adjusted EPS of $8.35–$8.50, and Q1 core revenue up low single digits with an operating margin of ~28.5%.
Jan 28, 2026, 1:00 PM
Danaher reports Q4 2025 earnings and 2026 guidance
DHR
Earnings
Guidance Update
- Danaher capped Q4 2025 with better-than-expected margins, earnings and cash flow, driven by high single-digit bioprocessing growth and improving diagnostics and life sciences end markets.
- Full year 2025: $24.6 B in sales (2% core growth), 28.2% adjusted operating margin, $7.80 EPS (+4.5%), and $5.3 B free cash flow (145% conversion).
- 2026 outlook: 3–6% core revenue growth and $8.35–$8.50 adjusted EPS, with Q1 revenue up low single digits and ~28.5% margin.
- Continued innovation: Cytiva rolled out 20+ biologics workflow products (e.g., new Xcellerex bioreactor formats) and SCIEX launched the ZenoTOF 8600 mass spectrometer.
Jan 28, 2026, 1:00 PM
Danaher reports Q4 2025 results and 2026 guidance
DHR
Earnings
Guidance Update
- Danaher delivered Q4 2025 sales of $6.8 B (core revenue +2.5%), adjusted EPS $2.23 (+4%), and free cash flow $1.8 B.
- For full year 2025, sales reached $24.6 B (core +2%), with an adjusted operating margin of 28.2%, adjusted EPS $7.80 (+4.5%), and free cash flow $5.3 B (145% conversion).
- Q4 segment trends: bioprocessing grew high-single digits, life sciences was flat (+0.5%), and diagnostics rose 2%.
- In diagnostics, Q4 respiratory revenue was $500 M, and FY2026 respiratory revenue is expected to be $1.8 B.
- 2026 outlook: core revenue growth of 3–6%, adjusted EPS $8.35–$8.50, Q1 revenue up low single digits with ~28.5% operating margin; continued strength in bioprocessing, modest life sciences recovery, and diagnostics growth.
Jan 28, 2026, 1:00 PM
Danaher reports Q4 2025 results
DHR
Earnings
Guidance Update
- Danaher reports Q4 2025 revenue of $6.838 B, up 4.5% year-over-year, driven by core growth of 2.5% and FX tailwinds of 2.5%.
- Adjusted diluted EPS rose to $2.23 (+4.0%), while Q4 free cash flow reached $1.769 B, up 17.5%.
- Segment performance: Biotechnology revenue +9.0% (core +6.0%), Life Sciences +2.5% (core +0.5%), Diagnostics +3.0% (core +2.0%).
- Q1 2026 core sales growth expected at low-single digit (biotech high-single digit, life sciences flat/-low-single digit, diagnostics ‑low-single digit); full-year 2026 core growth forecast 3.0–6.0%.
Jan 28, 2026, 1:00 PM
Danaher announces Q4 and full year 2025 results
DHR
Earnings
Guidance Update
- Q4 2025 net earnings of $1.2 billion ( $1.66 diluted EPS), non-GAAP EPS of $2.23, revenues up 4.5% to $6.8 billion, operating cash flow of $2.1 billion and free cash flow of $1.8 billion
- Full year 2025 net earnings of $3.6 billion ( $5.03 diluted EPS), non-GAAP EPS of $7.80, revenues up 3.0% to $24.6 billion, operating cash flow of $6.4 billion and free cash flow of $5.3 billion
- 2026 outlook: first quarter non-GAAP core revenue growth in the low-single digit range; full year core revenue growth of 3–6%; adjusted diluted EPS of $8.35–$8.50
Jan 28, 2026, 11:00 AM
Danaher reports Q4 and full year 2025 results
DHR
Earnings
Guidance Update
Product Launch
- Danaher reported Q4 2025 net earnings of $1.2 billion (GAAP) or $1.66 EPS and non-GAAP adjusted EPS of $2.23 (+4.0%), on revenues of $6.8 billion (+4.5% YoY), with operating cash flow of $2.1 billion and non-GAAP free cash flow of $1.8 billion.
- For full year 2025, GAAP net earnings were $3.6 billion (EPS $5.03) and non-GAAP adjusted EPS was $7.80 (+4.5%), on revenues of $24.6 billion (+3.0%), with operating cash flow of $6.4 billion and non-GAAP free cash flow of $5.3 billion.
- In 2025, Danaher launched key innovations including Cytiva’s expanded Xcellerex X-platform bioreactors (500L and 2,000L), SCIEX’s ZenoTOF 8600 mass spectrometer, an expanded DxI 9000 immunoassay menu, and Cepheid’s FDA-cleared Xpert GI Panel PCR test.
- Looking ahead, Danaher expects Q1 2026 non-GAAP core revenue growth in the low-single digit range and full-year 2026 core revenue growth of 3%–6%, with adjusted diluted EPS guidance of $8.35–$8.50.
Jan 27, 2026, 10:37 PM
Danaher pre-announces Q4 beat and outlines 2026 outlook at JPM Healthcare Conference
DHR
Guidance Update
M&A
- Danaher expects Q4 2025 core revenue growth at the high end of its low single-digit guidance, with full-year adjusted EPS towards the high end of $7.70–$7.80, driven by strong consumables and equipment momentum.
- For 2026, Danaher reaffirmed targets of 3–6% core revenue growth, >100 bps adjusted operating margin expansion, and high-single-digit adjusted EPS growth.
- The company, with ~$25 billion in revenue, operates three segments (biotechnology, life sciences, diagnostics), delivers ~80% recurring revenue, ~60% gross margins, ~30% operating margins, and >$6 billion in operating cash flow.
- Danaher’s capital allocation remains biased toward disciplined M&A, evaluating targets on secular growth, defensible market positions with value reserves, and financial returns, supported by a strong balance sheet.
Jan 13, 2026, 7:15 PM
Danaher previews Q4 2025 results and 2026 guidance at JPM Conference
DHR
Guidance Update
- Q4 2025 core revenue growth expected at the high end of low-single digits and FY 2025 adjusted EPS toward the high end of the $7.70–$7.80 range
- 2026 targets: 3–6% core revenue growth, >100 bps adjusted operating margin expansion, and high-single-digit adjusted EPS growth
- 2025E segment revenues: Diagnostics ~$9.9 B, Biotechnology ~$7.3 B, Life Sciences ~$7.3 B; financial profile includes 59.5% gross margin, 28.6% adj. op. margin, and >$6 B cash flow
- New product innovations spotlight the ZenoTOF 8600 mass spectrometer, Xcellerex X-platform bioreactors, and Dxl 9000 immunoassay analyzer to drive next-generation diagnostics and biomanufacturing
Jan 13, 2026, 7:15 PM
Danaher previews Q4 2025 results and 2026 guidance at J.P. Morgan Healthcare Conference
DHR
- Danaher expects Q4 2025 core revenue growth at the high end of low-single-digit guidance and FY 2025 adjusted EPS at the upper end of the $7.70–$7.80 range.
- For 2026, Danaher targets 3%–6% core revenue growth, >100 bp expansion in adjusted operating margin, and high-single-digit adjusted EPS growth.
- The $25 billion company operates in biotechnology, life sciences, and diagnostics with ~60% gross margin, ~30% operating margin, and 80% recurring revenue.
- Long-term secular drivers include an aging global population (1.5 billion aged 65+ by 2050), over 20,000 biologics in development, and a 2.5× expansion in molecular diagnostics since 2019.
- Recent product innovations include a high-sensitivity mass spectrometer, Cytiva’s Xcellerex X-platform (3× higher oxygen transfer), and Beckman’s DxI 9000 immunoassay enabling early Alzheimer’s detection via blood.
Jan 13, 2026, 7:15 PM
Quarterly earnings call transcripts for DANAHER CORP /DE/.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more